Effects of amphetamine on immune-mediated lung inflammatory response in rats

被引:19
|
作者
Ligeiro-Oliveira, AP
de Araújo, AMF
Lazzarini, R
Silva, ZL
De Nucci, G
Muscará, MN
de Lima, WT
Palermo-Neto, J
机构
[1] Univ Sao Paulo, Sch Vet Med, Appl Pharmacol & Toxicol Lab, Sao Paulo, Brazil
[2] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
amphetamine; allergic inflammation; bronchoalveolar lavage; metyrapone; bone marrow; corticosterone; sensitization;
D O I
10.1159/000076767
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The present study analyzed the effects of acute amphetamine (AMPH) treatment on immune-mediated lung inflammatory response in rats. Methods: There were four experiments. In the first and second experiments, rats were treated with AMPH (1 mg/kg) or 0.9% NaCl, and locomotor activity (experiment 1) and serum AMPH concentrations (experiment 2) were measured 1 or 12 h after treatment. In the third experiment, rats which were immunized with ovalbumin (OVA) were treated 14 days later with 0.9% NaCl or AMPH (1 mg/kg). Twelve hours after these treatments, all animals were submitted to challenge by 1% OVA inhalation being analyzed afterwards for bronchoalveolar lavage fluid (BAL), peripheral blood and bone marrow cellularity. In the fourth and final experiment, rats were treated and studied as for experiment 3, except that half of the animals within each group were previously treated with metyrapone prior to the OVA challenge. Results: In the nonimmunized rats, AMPH treatment induced an increase in locomotor activity synchronized to high serum AMPH concentrations 1 h after, but not 12 h after treatment. In OVA-challenged rats, AMPH treatment decreased the total number of inflammatory cells, recovered in both BAL and peripheral blood and increased the total number of bone marrow cells. These effects, observed 1 day after OVA challenge, were abrogated by previous metyrapone treatment. Conclusion: AMPH treatment changed HPA-axis responsiveness to the stress condition imposed by the OVA challenge decreasing lung and blood leukocytes cellularity most probably via corticosterone actions on bone marrow activity. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:181 / 190
页数:10
相关论文
共 50 条
  • [21] Immune monitoring and treatment in immune-mediated inflammatory diseases
    van Wijk, Femke
    de Bruin, Marjolein
    Leavis, Helen
    Nierkens, Stefan
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [22] Common mechanisms in immune-mediated inflammatory disease
    Firestein, GS
    Corr, M
    JOURNAL OF RHEUMATOLOGY, 2005, 32 : 8 - 13
  • [23] Psychiatric comorbidity in immune-mediated inflammatory diseases
    Marrie, Ruth Ann
    Bernstein, Charles N.
    WORLD PSYCHIATRY, 2021, 20 (02) : 298 - 299
  • [24] The role of platelets in immune-mediated inflammatory diseases
    Scherlinger, Marc
    Richez, Christophe
    Tsokos, George C. C.
    Boilard, Eric
    Blanco, Patrick
    NATURE REVIEWS IMMUNOLOGY, 2023, 23 (08) : 495 - 510
  • [25] Immune-mediated pathways in chronic inflammatory arthritis
    Gorman, Claire L.
    Cope, Andrew P.
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2008, 22 (02): : 221 - 238
  • [26] Social phobia in immune-mediated inflammatory diseases
    Reinhorn, Ian M.
    Bernstein, Charles N.
    Graff, Lesley A.
    Patten, Scott B.
    Sareen, Jitender
    Fisk, John D.
    Bolton, James M.
    Hitchon, Carol
    Marrie, Ruth Ann
    Walker, John R.
    Singer, Alexander
    Lix, Lisa M.
    Hitchon, Carol A.
    El-Gabalawy, Renee
    Katz, Alan
    Graff, Lesley
    Berrigan, Lindsay
    Zarychanski, Ryan
    Peschken, Christine
    Marriott, James
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 2020, 128
  • [27] The Gut Microbiota in Immune-Mediated Inflammatory Diseases
    Forbes, Jessica D.
    Van Domselaar, Gary
    Bernstein, Charles N.
    FRONTIERS IN MICROBIOLOGY, 2016, 7
  • [28] Biologics in Inflammatory Immune-mediated Systemic Diseases
    Moroncini, Gianluca
    Calogera, Giovanni
    Benfaremo, Devis
    Gabrielli, Armando
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2017, 18 (12) : 1008 - 1016
  • [29] Travelers With Immune-Mediated Inflammatory Diseases: Are They Different?
    Jaeger, Veronika K.
    Rueegg, Rolanda
    Steffen, Robert
    Hatz, Christoph
    Buehler, Silja
    JOURNAL OF TRAVEL MEDICINE, 2015, 22 (03) : 161 - 167
  • [30] A role for leptin in immune-mediated inflammatory diseases?
    C Gabay
    G Palmer
    Arthritis Res Ther, 6 (Suppl 3):